Image
Portfolio

Case study - CTRS

Laboratoires CTRS

  • >18
    Employees
  • 2002
    Creation Date
  • France
    Headquarters
  • 2020
    Investment Year
  • Mérieux Participations 3
    Fund Name
  • In Portfolio
    Status
  • Benoit Chastaing, Quentin de Labarre & Marie-Justine Lecomte
    Deal Team

Company profile

Laboratoires CTRS is a French pharmaceutical company focused on developing and marketing drugs for rare diseases. Its main areas of expertise are Hereditary metabolic diseases and Oncology-haematology-immunology.

CTRS has developed a smart and efficient business model thanks to its ability to secure strategic partnerships (strong and long-lasting relationship with AP-HP) combined with the ability to detect unmet needs (network of KOLs, management and doctors) and a smart regulatory strategy.

Investment thesis

A flexible model enabling CTRS to develop new products in a very cost-effective way (via co-development agreements; profit sharing; or exclusive license signatures).

CTRS is still highly active in business development and particularly in the search of treatments answering unmet needs and has currently 3 well-advanced products in its pipeline.

The company will develop new geographical markets (China, UAE, USA) for its core product.

Added value by MxEP

Since its investment in CTRS in 2020, MxEP has provided support to the company on several fronts such as:

  • Support to the market access for one product in China through Institut Mérieux’ strong relationship with local regulatory bodies 
  • Help on the strategic review and go-to-market strategy for the USA through one portfolio company experience sharing 
  • Introduce and/or assess new products on an ongoing basis, which could be of interest to CTRS
  • Give CTRS access to MxEP’s experts network to find the relevant partners (CDMOs, distributors, etc.) 
  • Support on reimbursement strategy for one product in France by giving access to MxEP’s network
ANTOINE FERRY
CEO OF CTRS

We are extremely pleased about Mérieux Equity Partners becoming a shareholder of reference since, in addition to fully sharing our ethical values and innovation spirit, they provide us with active support on our international development. This will enable us to continue our great adventure in the sole interest of patients.